India's Shaily Engineering rises after UBS notes likely gain from Zydus diabetes drug row
BUZZ-India's Shaily Engineering rises after UBS notes likely gain from Zydus diabetes drug row ** Shaily Engineering SEPL.NS rises as much as 3.69% to 3,184 rupees
** UBS notes plastics and pharma packaging maker as potential beneficiary after Delhi High Court on Wednesday directed drug regulator CDSCO to review Zydus Lifesciences' ZYDU.NS semaglutide injection approval
** "Potential change in vendor could open opportunity for SEPL after a diabetes patient alleged that ZYDU departed from the global practice of pre-filled, pre-calibrated pen devices," says UBS
** UBS retains "buy", PT 4,000 rupees, implying 30.3% upside from last close
** Average rating of six analysts on SEPL is "strong buy" with median PT at 3,477 rupees - LSEG-compiled data
** SEPL up about 36% in 2026 so far
(Reporting by Bharath Rajeswaran in Bengaluru)
((bharath.rajeswaran@thomsonreuters.com; +91 9769003463;))
Recent news on Shaily Engineering Plastics
See all newsIndia's Shaily Engineering rises after UBS notes likely gain from Zydus diabetes drug row
Brief: Shaily Engineering Says Orbicular Pharma Launched Generic Of Semaglutide Injection In Canada, Incorporating Co’S Pen Platform
India's Shaily Engineering rises on 4.23 billion-rupee order win
Brief: Shaily Engineering Plastics Gets Contract Worth About 4.23 Billion Rupees
India's Shaily Engineering rises as UBS initiates with 'buy' rating